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Comparative genomic hybridization analysis of a primary osteosarcoma and its metastasis revealed two regions of DNA  
amplification, one at I7pl 1.2-12 and one at !9q I2-l3 . Subsequent representational difference analysis of the primary tumor 
resulted in the isolation of two distinct tumor-amplified DNA fragments originating from chromosome 19. A YAC clone 
corresponding to one of the two isolated DNA fragments was used for fluorescence in situ hybridization on normai human 
lymphocyte metaphases and tumor-derived nuclei. This resulted in the localization of this YAC to 19q 12-13-1 and confirmed 
the amplification status of the isolated fragment in the tumors. The availability of such RDA-isolated sequences may 
be instrumental in the search for genes relevant for tumor development. Genes Chromosomes Cancer 20:196-200, 1997.
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Cytogenetic studies of osteosarcomas have re­
vealed highly aneuploid and extremely complex 
karyotypes with numerous abnormalities, including 
homogeneously staining regions, double minutes, 
and supernumerary ring chromosomes (Fletcher et 
aL, 1994; Sandberg and Bridge, 1994; Heim and 
Mitelman, 1995). Osteosarcoma-associated chromo­
somal alterations include loss or rearrangement of 
chromosome bands 13ql4 and 17p 13, harboring the 
R B I  and TP53 tumor suppressor genes, respec­
tively (Toguschida et al., 1988,1989; Scheffer et al., 
1991). Homogeneously staining regions, double 
minutes, and/or ring chromosomes appear to be 
associated with gene amplification, as has been 
demonstrated, for instance, for the M YC  oncogene 
on chromosome 8 (Ozaki et al., 1993) and the 
MDM2 gene on chromosome 12 (Ladanyi et al.,
1993). Previously, it has been shown that the 
technique of comparative genomic hybridization 
(CGH; Kallioniemi et al, 1992) is suitable for the 
detection and mapping of (sub)chromosomal losses, 
gains, and amplifications in osteosarcomas (Forus et 
al., 1995b; Tarkkanen et al, 1995; Geurts van 
Kessei et al., 1997).
The isolation of DNA fragments that are deleted, 
rearranged or amplified in tumors can be achieved 
using the more recently developed technique of 
representational difference analysis (RDA; Lisitsyn 
et al., 1993,1995; Lisitsyn, 1995). This technique is 
based on subtractive hybridization of two DNA 
populations (tester and driver), followed by specific 
polymerase chain reaction (PCR) of the differences
(tester-specific) between the DNA populations. To 
gain further insight into the molecular genetic changes 
that are relevant for the development of osteosarcomas, 
we have combined CGH and RDA for the analysis 
of a primary osteosarcoma and its metastasis.
An osteosarcoma sample (T87) was obtained 
from the right distal femur of a 15-year-old female 
patient after chemotherapy. Histopathologic exami­
nation showed a high-grade medullary osteoblastic, 
partly fibroblastic osteosarcoma with hyalinization 
and abundant osteoid formation. No cytogenetic 
data could be obtained from this tumor. Two years 
later, the same patient developed a metastasis (T95) 
in the right ilium, which showed the same histopatho­
logic characteristics as the primary tumor. Cytoge­
netic analysis revealed several clonal structural 
abnormalities, including marker chromosomes: 
65,X,—X ,—X, —I,del(l)(p31),add(l)(p36),—2,--2J 
— 2,-3,add(3)(p26),del(4)(pl5)X2,add(4)(pl6),—5,
-6 ,a d d (6 )(p 2 5 ),-7 ,-8 ,-9 ,-1 0 ,d e l(1 0 )(p ll) ,- ll, 
- 1 2 ,- 1 3 ,  —14, —15,-16, —16, — 18,del(18)(pl2), 
- 1 9 ,—20,-21 ,-2 2 , + 21mar [2]. At least four of the
marker chromosomes and the abnormal chromo­
somes add(3)(p26) and add(6)(p25) were clearly 
recognized in four to six other metaphases.
To characterize the genomic alterations in more 
detail, we performed CGH as described previously
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by Forus et al. (1995a,b). DNAs extracted from the 
primary tumor and its metastasis were compared to 
reference DNA isolated from peripheral blood cells 
of normal control persons. Two sites of overt 
amplifications could easily be recognized in both 
the primary tumor and its metastasis, one at
17pl 1.2-12 and one at 19ql2-13 (Fig. 1A). A mini­
mum of eight target chromosome homologues was 
assayed for imbalances using arbitrarily set thresh­
olds for gains and losses of chromosomal (subre­
gions, 1.25 and 0.75, respectively (du Manoir et al., 
1993, 1995). As was seen before, two regions of gain 
were detected in both tumors, one on 17p, with the 
highest ratio value at 17pl 1.2-12, and one on 19q, 
with the highest ratio value at 19ql2-13 (Fig. IB). 
Complete suppression of heterochromatic regions 
of critical chromosomes (1, 9,16, and 19; Du Manoir 
etaL, 1995) was observed, indicating that the signal 
of gain on 19ql2-13 is genuine. Other copy number 
alterations could not be detected in the tumor 
DNAs under the stringency conditions applied* 
Although in this study no cytogenetic data of the 
primary tumor was available, a genetic comparison 
of the primary tumor and its metastasis based on 
CGH results was still possible. We conclude that no 
CGH-detectable changes appear to have occurred 
after metastasis of the primary tumor.
Using whole chromosome 17 and 19 painting 
probes, we performed fluorescence in situ hybridiza­
tion (FISH) on metastasis-derived metaphase 
spreads to localize these sequences within the 
tumor genome. The paints, detected in different 
colors, showed hybridization to at least five marker 
chromosomes (not shown). This indicates that extra 
material of chromosomes 17 and 19 is cryptically 
present in these marker chromosomes, which is in 
agreement with the CGH findings.
With the observed highly abnormal karyotype 
and the DNA amplifications detected by CGH, we 
set out to isolate aberrant, in particular, amplified, 
DNA fragments from the primary tumor via RDA. 
In the case of amplifications, the isolation of target 
sequences is based on their relative abundance in 
the tester, which leads to kinetic enrichment during 
the RDA procedure, and not on their absence in the 
driver (Lisitsyn 1995; Lisitsyn et al., 1995). RDA 
was performed essentially as described by Lisitsyn 
et al. (1993, 1995) using representations of primary 
tumor DNA (the tester) and of a DNA pool of five 
unrelated control persons (the driver). Representa­
tions were made by BgM  cleavage of genomic DNA  
and subsequent PCR amplification using its corre­
sponding anchor primers (Lisitsyn et aL, 1993). 
Agarose gel electrophoresis of difference products
A
Figure ], A : CGH result showing amplifications on 17p 11.2-12 
(arrowheads) and I9q[2-I3 (arrows) as encountered in both the 
primary tumor and its metastasis. Shown is a partial normal male 
metaphase spread after cohybridization with reference (red) and test 
(tumor T87; green) DNAs as probes. The chromosomes are counter­
stained in blue. B: Schematic representation of the average fluorescence 
ratio profiles of chromosomes 17 and 19 after CGH with T87 DNA as 
test probe. Profiles are plotted to the right of the chromosomes. The 
vertical lines reflect the lower threshold (left), the ratio value of I 
(middle), and the upper threshold, respectively. Two peaks of overrep­
resentation can be seen at I7pand I9q.
after one, two, and three rounds of subtractive 
hybridization and PCR amplification is shown in 
Figure 2. Five clear bands, varying in size from 300 
to 500 bp, could be observed in the round 3 
difference product, whereas background levels were 
reduced considerably. These five bands were iso­
lated out of gel and cloned into plasmids. Subse­
quently, the cloned fragments were used as probes 
on Southern blots containing tester and driver 
(representation and total genomic) DNAs. Two 
distinct clones (clone 18 of 471 bp and clone 38 of 
330 bp, derived from bands 5 and 2, respectively) 
showed more intense hybridization signals in the 
tester lanes than in the driver lanes, indicating that 
these fragments represent amplified sequences as 
present in the original tumor (Fig. 3). Also in the 
metastatic tumor, these sequences appeared to be 
highly amplified (not shown). Other clones, derived 
from all five bands, showed similar intensities in
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Figure 4. Chromosomal localization of clone 38 by PCR analysis of 
monochromosomal somatic cell hybrid lines (1-22, X, and Y). Mouse 
(m), hamster (h), and no (—) DNAs were used as negative controls, 
whereas tester (T), driver (D), and clone 38 (38) DNAs were used as 
positive controls. A PCR product was revealed only in the chromosome 
19-containing cell hybrid, demonstrating that clone 38 maps to this 
chromosome.
Figure 2. RDA results of tumor T87 as tester and a pool of five 
normal DNAs as driver. Tester: Bg/ll representation of tumor DNA. 
DPI, DP2, and DP3: Difference products after first, second, and third 
round of hybridization/amplification, respectively, In DP3, five bands 
appear (1—5), which represent target sequences enriched from the 
tumor DNA.
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chromosomal localization of these clones via PCR 
analysis of monochromosomal somatic ccll hybrid 
lines* we used primer sets designed from both
clones (18FOR: 5'AGTGTGTACCTGGCAGC- 
GGC-3' and 18REV: 5'TCTCATATGCCTGGGT- 
GATGGA-3'; 38FOR: 5 'T-TC AGC ATGATCCC A- 
ATCAAAA-3' and 38REV: 5'ATAAACCCCAG- 
C ACAATTAGCC-3'). PCR products of expected 
sizes (355 bp with the 18FOR/REV primer set and 
205 bp with the 38FOR/REV primer set) were
observed only in the chromosome 19-containing 
somatic cell hybrid, indicating that both clones map 
to this human chromosome (Fig. 4).
To reconfirm the chromosomal origin of clones 18 
and 38 by visualization with FISH, a human YAC 
library (Anand et al., 1990; YAC plugs from UK 
HGMP Resource Centre) was screened by PCR 
with the FOR/REV primer sets. One clone 38- 
positive YAC (19B-A6) of approximately 400 kb was 
isolated. FISH analysis with this YAC on high- 
resolution normal human m eta phase spreads re­
vealed positive signals at 19q 12-13.1 only, which is 
in line with the localization of the corresponding 
DNA fragment (clone 38) on chromosome 19. In 
addition, YAC 19B-A6 maps to a region exactly 
coinciding with the region of amplification as ob­
served by CGH (Fig. 5).
tester and driver lanes on Southern blots, indicating Subsequently, YAC 19B-A6 was used for inter-
that they represent sequences that have escaped phase FISH analysis of the metastasis. In all nuclei
- 600 bp
- 500 bp
- 400 bp
- 300 bp
Figure 3. Hybridization of clone 38 to Southern blots containing 
Bgill-representation DNAs and figlil-cleaved total genomic DNAs of 
driver (normal) and tester (tumor T87). Clone 38 sequences are 
overrepresented in the tester DNA compared to the driver DNA.
the RDA subtraction.
Clones 18 and 38 were sequenced and, subse­
quently, compared to known sequences in the 
Genbank and EMBL databases. No relevant ho­
mologies could be found for either. To establish the
examined (over 50), four separate clusters of mul­
tiple copy signals could be observed. Examples of 
tumor nuclei exhibiting these clusters of amplifica­
tion are shown in Figure 6. For comparison, two 
YAC signals on a normal lymphocyte nucleus are
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also shown. These results confirm that the corre­
sponding sequences are amplified in the osteosar­
coma studied.
Although it has not been reported before that the 
19ql2-13 region is frequently amplified in osteosar­
comas, it has recently been found that it is a hot 
spot for structural abnormalities in these tumors
Figure 5. Chromosomal localization of YAC 19B-A6 by FISH on 
normal high-resoiutlon metaphase chromosomes. A specific hybridiza­
tion signal (green) can be seen at 19q 12-13.1 (arrowheads, left). 
Chromosomes are counterstained in red (left). Chromosomal identifica­
tion is performed using computer-inverted DAPI-banding (right).
(Bridge et al., 1997). In addition, this 19q segment 
has occasionally been shown to be amplified in 
ovarian cancers (Cheng et al., 1992; Thompson et 
al., 1996). At least four candidate genes are located 
in this region: 1) A K T2 , a gene encoding a Ser/Thr
kinase (Cheng et al., 1992); 2) ERCC2, a DNA  
repair gene (Thompson et al., 1996); 3) BCL3 , 
encoding a DNA binding inhibitor of transcription 
factor NF-kp (Hatada et al„ 1992); and 4) TGFB, 
which is involved in the differentiation of mesenchy­
mal cells to chondrocytes and osteoblasts (Fuiji et 
al., 1986). However, the role of these genes in the 
pathogenesis of osteosarcomas remains to be estab­
lished, and it should be kept in mind that other 
candidate genes might be located within the 
19ql2-13 region as well. Although the clone 18 and 
38 sequences did not exhibit open reading frames 
or relevant homologies with known sequences, 
they may be located close to such a gene or genes. 
No fragments from the amplification region on 
chromosome 17 were isolated in this RDA experi­
ment, which may be explained by the fact that 
success depends on the restriction enzyme used 
and the presence of its restriction sites within the
amplified segment. The 17pl 1.2-12 region may
also harbor genes that are relevant for osteosarcoma 
development. This suggestion is based on our 
present and the previously reported CGH studies 
on osteosarcomas, indicating a frequent high-copy 
amplification of this region in these tumors. Cur­
rently, we are isolating DNA fragments from this
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Figure 6. FISH analysis of normal lymphocyte and tumor T95-derived nuclei using YAC I9B-A6 as a 
probe (green). Multiple signals can be seen in the tumor nuclei (B) compared to the two signals (arrowheads) 
in the normal situation (A). Nuclei are counterstained in red.
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region. These fragments and the chromosome 19- 
derived sequences reported here may be instrumen­
tal in the identification and isolation of relevant 
(onco)genes*
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